---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-232464"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2023-09-11T23:59:59+00:00"
generated_at: "2026-06-10T21:56:03.528473+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# XOMA receives $4.9M commercial payment from Genentech for VABYSMO H1 2023 sales

## Summary
- Received $4.9 million from Genentech (Roche) for VABYSMO net sales in first six months of 2023.
- Payment reflects 0.5% royalty stream on VABYSMO sales in certain regions for ten years from first commercial sale.
- XOMA acquired this royalty interest through an October 2021 purchase agreement with Affitech Research AS.

## SEC filing metadata
- accession: 0001193125-23-232464
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2023-09-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312523232464/0001193125-23-232464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312523232464/d348732d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-232464
- JSON: https://secwatch.observer/filing/0001193125-23-232464.json
- Plain text: https://secwatch.observer/filing/0001193125-23-232464.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.